Clinical Trials

DENVER — A phase 3 trial of ulixacaltamide for essential tremor will involve at-home patient participation and a clinical endpoint of activities of daily living, according to a speaker at the American Academy of Neurology annual meeting.

ATLANTA — In this Healio video exclusive, Pamela S. Douglas, MD, MACC, FASE, FAHA, discusses an American College of Cardiology initiative created to increase diversity and equity in clinical trials research leadership.

A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease.

Neurocrine Biosciences Inc. announced a phase 1 study to evaluate an investigational neuropsychiatric therapy in healthy adults, as well as commencement of dosing in a phase 2 study of a novel oral compound for major depressive disorder.

A United Kingdom-based clinical-stage biotech company has announced commencement of a first-in-human clinical trial of a selective central nervous system-penetrant compound to treat Parkinson’s disease.

March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.

WEST PALM BEACH, Fla. — Inclusion of underrepresented racial and ethnic groups, along with older patients, patients from rural areas and uninsured patients in multiple sclerosis-targeted clinical trials is likely to improve outcomes, according to a speaker.

Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.

WEST PALM BEACH, Fla. — Treatment with evobrutinib was nonsuperior to teriflunomide in confirmed disability progression at 12 and 24 weeks for those with relapsing forms of multiple sclerosis, according to a presenter at ACTRIMS 2024.

An FDA Oncology Center of Excellence program titled “Real Talk: Our Stories as Black Oncologists at the FDA” included discussion about how to increase diversity in clinical trials.